Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG867

—

114d5048-c483-5cb2-b893-5487085bbba9

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.364
  • INFLAMMATORY_RESPONSE+0.363
  • ANGIOGENESIS+0.355
  • COMPLEMENT+0.332
  • KRAS_SIGNALING_UP+0.310
  • IL6_JAK_STAT3_SIGNALING+0.305
  • APICAL_SURFACE+0.302
  • WNT_BETA_CATENIN_SIGNALING+0.300
  • HEDGEHOG_SIGNALING+0.285
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.280

Top 10 suppressed

  • E2F_TARGETS-0.317
  • G2M_CHECKPOINT-0.288
  • MYC_TARGETS_V2-0.280
  • MYC_TARGETS_V1-0.143
  • PROTEIN_SECRETION-0.139
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.103
  • MITOTIC_SPINDLE-0.085
  • DNA_REPAIR-0.062
  • BILE_ACID_METABOLISM-0.027
  • SPERMATOGENESIS-0.018

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1313138
breast-umap@18
—D0.869
2MBCProject_0734_T1A_RNA
breast-umap@18
—A0.863
3BS_RRAEQZ97
brain-umap@2
pilocytic astrocytoma—0.859
4BS_EFEZB0ZH
brain-umap@2
low-grade glioma—0.859
5C3L-02552
lung-landscapes@6
—cohortSQ10.858
6GSM5359409
bladder-landscape@3
——0.858
7MBCProject_0419_T2_RNA
breast-umap@18
—A0.857
8SJEPD009_D.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.854
920060029.TNBC
breast-umap@18
—D0.854
10SRR23303755
bladder-landscape@3
——0.853

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 38 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.364Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.363Idelalisib— uncovered
ANGIOGENESIS0.355Remibrutinib— uncovered
COMPLEMENT0.332Inavolisib— uncovered
KRAS_SIGNALING_UP0.310Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.305Inavolisib— uncovered
APICAL_SURFACE0.302Temsirolimus— uncovered
WNT_BETA_CATENIN_SIGNALING0.300Inavolisib— uncovered
HEDGEHOG_SIGNALING0.285Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.280Inavolisib— uncovered
TGF_BETA_SIGNALING0.263Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.253Idelalisib— uncovered
P53_PATHWAY0.249Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.249Inavolisib— uncovered
ADIPOGENESIS0.222Inavolisib— uncovered
UV_RESPONSE_DN0.218Inavolisib— uncovered
COAGULATION0.213Binimetinib— uncovered
FATTY_ACID_METABOLISM0.209Inavolisib— uncovered
MYOGENESIS0.208Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.207Inavolisib— uncovered